EMEA-000804-PIP01-09-M02

Key facts

Invented name
Reyataz
Active substance
Atazanavir (sulphate)
Therapeutic area
Infectious diseases
Decision number
P/0098/2014
PIP number
EMEA-000804-PIP01-09-M02
Pharmaceutical form(s)
  • Capsules
  • Hard oral powder
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
United Kingdom
E-mail: medical.information@bms.com
Tel. +44 (0)1895 523740
Fax +44 (0)1895 523677
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000804-PIP01-09-M02
Compliance opinion date
13/02/2015
Compliance outcome
positive

Decision

How useful was this page?

Add your rating